Mednet Logo

Have your treatment recommendations for urothelial cancer patients changed given the ongoing COVID19 pandemic?

Would you forego neoadjuvant chemotherapy? Are you using growth factor support differently? Any changes to immunotherapy? Other considerations?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Vanderbilt-Ingram Cancer Center
Answered on

The therapeutic approach to cancer patients is changing rapidly due to the COVID-19 pandemic. In discussing with colleagues from several different countries, a few themes emerge.

Patient visits, surgery, and treatment that is not essential is being deferred. The benefit/risk that we each consider fo...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington School of Medicine
Answered on

Excellent comments and answer by @Dr. First Last! Cancer is also a big threat to many patients. It is very hard to make hard & fast decisions in these situations; it is usually a case by case approach, balancing very carefully risks vs benefits, and discussing rationale, data, logistics, details of ...

Join for free or sign in to see the full answer